Skip to main content

Specialty Pharmacy

  • NASP launches medical marijuana task force

    ALEXANDRIA, Va. — The National Association of Specialty Pharmacy has launched a task force to investigate pharmacological management of medical marijuana, the group said.

    Currently, according to NASP, there are no national standards of practice for the management of medical marijuana, though according to the National Organization for the Reform of Marijuana Laws, 21 states and the District of Columbia have legalized marijuana for medical purposes. Two of those states, Washington and Colorado, have legalized recreational use as well.

  • APhA, NACDS, NCPA join biosimilar naming debate

    NEW YORK — Three pharmacy groups are petitioning the World Health Organization to uphold common generic names for biosimilars and their branded reference products.

  • FDA approves first single-entity, extended-release hydrocodone drug

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new opioid painkiller made by Zogenix, the agency said Friday.

    The FDA announced the approval of Zohydro ER (hydrocodone) extended-release capsules for the management of pain severe enough to require daily, around-the-clock, long-term treatment. The agency said the drug was the first extended-release hydrocodone product not combined with another drug, such as acetaminophen, to be approved by the agency.

  • ACHC renews accreditation for Axium Healthcare Pharmacy

    LAKE MARY, Fla. — A group that accredits healthcare organizations has renewed its certification for the Kroger Co.'s specialty pharmacy division.

    Axium Healthcare Pharmacy said Wednesday that it received a renewal of its accreditation status from the Accreditation Commission for Health Care for its specialty pharmacy services.

  • FDA designates Merck hepatitis C drug as breakthrough therapy

    WHITEHOUSE STATION, N.J. — The Food and Drug Administration has granted breakthrough therapy designation to an experimental drug made by Merck for hepatitis C, the drug maker said.

  • FDA approves subcutaneous Actemra for rheumatoid arthritis

    SOUTH SAN FRANCISCO, Calif. — The Food and Drug Administration has approved a new formulation of a drug made by Genentech for rheumatoid arthritis that can be injected into the skin.

    Genentech announced the approval of a subcutaneous formulation of Actemra (tocilizumab) in adults for adults with moderate RA who have not found sufficient relief by taking such disease-modifying antirheumatic drugs as methotrexate. Like the intravenous formulation of Actemra, the new version can be used alone or with drugs like methotrexate.

  • BioRx launches hemophilia smartphone app

    CINCINNATI — A mobile app described as the specialty pharmacy industry's first for patients with hemophilia has become available.

  • Clinical trial results support experimental Gilead drug for hepatitis C as safe, effective, FDA records show

    NEW YORK — An experimental drug under development by Gilead Sciences for hepatitis C is safe and effective when combined with other treatments, according to a review posted on the Food and Drug Administration's website ahead of an expert panel meeting to take place Friday.

X
This ad will auto-close in 10 seconds